MURA

Mural Oncology Plc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website muraloncology.com
Employees(FY) 110
ISIN IE000LK2BOB4

Performance

-5.99%

+16.98%

+3.51%

+9.02%

+14.44%

YTD

-16.06%

Profile

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Advanced Technical Analysis

Technical Analysis of MURA 2025-01-31

The stock exhibits a bullish sentiment with a Moving Average Score of 76, indicating strong upward momentum, while the Oscillators Score of 33 suggests some bearish pressure. Overall, the Technical Score of 58 reflects a neutral stance, implying that despite the strong moving averages, caution is warranted due to the oscillators' weakness.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MURA

Stock Rank

Recent News & Updates

2025-01-09 03:00
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts(Globenewswire)
2024-12-03 03:15
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-23 17:10
Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks(Yahoo Finance)
2024-11-20 03:15
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer(Globenewswire)
2024-11-12 18:00
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress(Globenewswire)
2024-11-10 18:00
Mural Oncology to Participate in Two Upcoming Investor Conferences(Globenewswire)
2024-11-07 03:15
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)(Globenewswire)
2024-11-04 03:15
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-06 19:00
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)(Globenewswire)
2024-10-02 04:15
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-09-25 19:00
Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress(Globenewswire)
2024-09-22 19:00
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi(Globenewswire)
2024-09-09 19:00
Mural Oncology to Host First Virtual Investor Day on September 26, 2024(Globenewswire)
2024-09-04 04:30
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-08-26 19:00
Mural Oncology to Present at Two Upcoming Investor Conferences(Globenewswire)
2024-08-12 19:15
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress(Globenewswire)
2024-08-02 04:15
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-07-30 19:00
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors(Globenewswire)
2024-07-02 04:15
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-06-05 04:15
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference(Globenewswire)
2024-06-04 04:00
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-05-23 05:00
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting(Globenewswire)
2024-05-14 01:55
MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024(Investorplace)
2024-05-13 19:00
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-05-03 04:00
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-24 04:00
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-04-09 04:00
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting(Globenewswire)
2024-04-04 04:00
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-03-26 01:53
MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023(Investorplace)
2024-03-25 19:00
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.